Early-onset cancer rates rose in all three countries, but not in the same way
An analysis of data from England, the United States and the Netherlands shows substantial increases in several cancers among people under 50, while leaving their causes unresolved.
By
Owen Caldwell
Early-onset cancer incidence increased significantly for several cancer types examined in England, the United States and the Netherlands, although the pattern differed in each country. The World Cancer Research Fund analysis found significant rises in seven types in England, five in the US and four in the Netherlands. In England, particularly large proportional changes included prostate cancer among men under 50 and bowel cancer among people in the same age group.
The analysis concerns incidence, which measures new diagnoses relative to population size, rather than case totals alone. This distinction helps put the increases into perspective. A rate of 8.4 per 100,000 describes how frequently diagnoses occurred in the relevant population, while a percentage change shows how far that rate moved from its starting level. A large relative increase can therefore begin from a low incidence.
The three national datasets indicate that the trend extends beyond a single registry, but they do not show that every cancer is becoming more common among younger adults in every country. The Guardian’s report on the World Cancer Research Fund analysis records different numbers of significantly increasing cancer types in the three countries. That variation is central to understanding the findings.
England’s largest shifts began from different baselines
Four of the clearest comparisons from England cover prostate, bowel, uterine and kidney cancers. Among men younger than 50, prostate cancer incidence rose from 1 diagnosis per 100,000 in 2001 to 3.6 per 100,000 in 2023. The later rate was 3.6 times the earlier one, but still represented fewer than four diagnoses per 100,000 men in that age group.
Bowel cancer started at a higher rate and produced a larger absolute change. Among people under 50, incidence increased from 3.9 per 100,000 in 2001 to 8.4 per 100,000 in 2023. This was a rise of 4.5 diagnoses per 100,000 across the period. The proportional increase was smaller than for prostate cancer, even though the difference between the starting and latest rates was greater.
Early-onset uterine and kidney cancer rates also doubled, reaching 3.9 and 3 per 100,000 respectively. The Irish Examiner’s account of the findings reports those changes alongside the prostate and bowel cancer figures.
| Cancer type in England | Earlier incidence | 2023 incidence | Scale of change |
|---|---|---|---|
| Prostate cancer, men under 50 | 1 per 100,000 in 2001 | 3.6 per 100,000 | 3.6 times the 2001 rate |
| Bowel cancer, people under 50 | 3.9 per 100,000 in 2001 | 8.4 per 100,000 | More than doubled |
| Early-onset uterine cancer | Not stated in the reported comparison | 3.9 per 100,000 | Doubled |
| Early-onset kidney cancer | Not stated in the reported comparison | 3 per 100,000 | Doubled |
The uterine and kidney figures communicate the size and latest level of the increase, but their original rates and starting dates are not included in the reported comparison. They cannot be assessed with the same numerical detail as the prostate and bowel series. The table consequently preserves that difference instead of supplying estimated baselines.
The US and Dutch results do not reproduce England’s pattern
In the United States, kidney cancer offers a direct comparison across time. Its incidence among people under 50 rose from 2.5 per 100,000 in 2000 to 5.3 per 100,000 in 2023. That represents an absolute increase of 2.8 diagnoses per 100,000, with the latest rate slightly more than twice the initial figure.
The analysis found five early-onset cancer types with significant increases in the United States, compared with seven in England. The reported results therefore identify a broad trend without establishing a shared national profile. Even where the same cancer appears in more than one country, the available periods and incidence levels are not necessarily identical.
In the Netherlands, significant increases involved bowel, kidney, liver and cervical cancers. Bowel and kidney cancer consequently overlap with England’s rising categories, while kidney cancer also appears in the US comparison. Cervical cancer distinguishes the Dutch group from the specific English and US examples reported here.
These overlaps matter, but so do the differences. The analysis does not support treating the countries as interchangeable or combining their figures into one rate. Each registry covers its own population, and the reported number and combination of rising cancer types varies by country. Broader questions about how major research institutions shape scientific work provide a separate perspective on the international research environment, rather than evidence about these cancer trends.
Rising rates do not mean cancer is common below 50
Cancer remains uncommon among people younger than 50, and the median age at diagnosis remains above 60. This context does not cancel the reported increases, but it changes how they should be read. The prostate cancer rate in England, for example, rose sharply in proportional terms because it started at 1 diagnosis per 100,000. By 2023, it remained below 4 per 100,000.
Absolute and relative changes answer different questions. Relative change reveals the speed of movement from an earlier level. Absolute incidence indicates how frequently diagnoses occur in the population. Both are needed to describe an early-onset trend without presenting uncommon cancers as though they had become common among all younger adults.
The findings also apply specifically to the countries, age groups, cancer types and periods analyzed. They do not establish that early-onset incidence is rising at the same pace worldwide. Nor do the totals of seven, five and four mean that the same cancers increased in every dataset. The international comparison demonstrates variation as well as a common direction for some cancers.
The trend is documented, but its causes remain unresolved
The analysis identifies changes in incidence and does not determine what caused them. It does not show that one behavior, exposure or demographic shift accounts for the increases, and it cannot attribute an individual diagnosis to a particular risk factor. The reasons for the different national patterns also remain unresolved.
Greater awareness of symptoms and earlier diagnosis may contribute to an increase in recorded cases. If more younger adults seek medical attention, or if testing identifies cancers that previously went undetected, incidence records can rise. However, the World Cancer Research Fund’s assessment indicates that improved detection does not account for the whole increase.
This leaves an important distinction between a plausible contributor and a demonstrated cause. Factors associated with cancer risk may help guide further research, but the country-level trends alone do not prove that those factors produced the observed changes. The figures describe when and where diagnoses became more frequent, not the biological or social mechanism behind every increase.
The reported material also does not include the underlying paper, detailed methodology or confidence intervals. Readers can compare the published rates and the stated direction of change, but cannot use these reports alone to evaluate the statistical precision behind every estimate. The clearest interpretation is therefore narrow but consequential: several early-onset cancer rates rose significantly across three countries, the affected cancers and scale differed by location, and the explanation remains incomplete.
Featured image. Source: Pexels. Credit: Anna Shvets. License: Pexels License.
